[Current development of glucocorticoid-targeting drugs].
Pharmacologically, glucocorticoids are estimated to be used long-term by 0.5-1% of the general population and up to 2.5% of older adults. Despite the established role of glucocorticoids in controlling short-term inflammation, and despite emerging evidence supporting a disease-modifying role in various autoimmune disorders, concern for adverse events associated with glucocorticoids often limits their use. The glucocorticoid compounds bind the glucocorticoid receptor(GR), which is a member of the nuclear receptor superfamily, and elicits their pharmacological actions. In this article, I will summarize recent understanding of the molecular mechanism of glucocorticoid action and discuss rationale to develop novel glucocorticoid-like compounds to dissociate their therapeutic effects and adverse reactions.